Loading...
StocksRunner logo
 
 
AbbVie
139.04
+1.02%
 
ABBV AbbVie
Last Price
Change
139.04
 
+1.02%
 
 
 

 
Sentiment
 
 

153.95

154.22

144.84

152.49

 
 
1m
3m
6m
1y
 

Summary

  Login to display AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Investors confidence is positive

Rewards

 Trading below its fair value

Rewards

 Pays a reliable dividend

 

Risk Analysis

Risk Analysis

 Earnings are forecast to decrease

Risk Analysis

 Downgraded on weak valued

Risk Analysis

 Enter oversold territory

Risk Analysis

 Insider selling during the past 3 months

 
 

Risk Level

 
StocksRunner
 

AbbVie (ABBV) has Low Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

2.91
 

StocksRunner

 Earnings decline YoY

StocksRunner

 Sales decline

 
 

Rating

×
 

Rating

3.67
 

StocksRunner

 Downgraded on weak valued

 

Momentum

×
 

Momentum

2.22
 

StocksRunner

 Price value has negative momentum

StocksRunner

 Enter oversold territory

 

Activity

×
 

Activity

3.62
 

StocksRunner

 Investors confidence is positive

StocksRunner

 Pays a reliable dividend

StocksRunner

 Insider selling during the past 3 months

 

Future

×
 

Future

3.40
 

StocksRunner

 Earnings are forecast to decrease

StocksRunner

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
47%
67%
0%
60%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
47%
43%
Positive
Negative
37 out of 79
events present
34 out of 79
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Investors Selling
This Week
136.87
+2.57%
 
Options Activity
3 Weeks Ago
146.56
+0.11%
 
Strong Earnings
3 Weeks Ago
146.52
-0.21%
 
Investors Selling
2 Month Ago
147.26
-0.52%
 
Options Activity
2 Month Ago
152.03
-1.09%
 
Top Headlines

$100 invested in abbvie 10 years ago would be worth this much today. abbvie (nyse:) has outperformed the market over the past 10 years by 2.04% on an annualized basis producing an average annual return of 12.13%. currently abbvie has a market capitalizati

Wed Jun 7, 2023

Activity

abbvie unusual options activity. someone with a lot of money to spend has taken a bearish stance on ). and retail traders should know. we noticed this today when the big position showed up on publicly available options history that we track here at benz

Fri Jun 2, 2023

Activity
Activity
Momentum
Potential

coherus biosciences to launch humira biosimilar at 85% discount. coherus biosciences inc said on thursday it plans to launch a biosimilar of abbvie incs humira in july at a list price of $995 per carton representing a discount of about 85% from

Thu Jun 1, 2023

Activity

why abbvie and amgen are moving lower today. what happened shares of the immunology juggernaut abbvie (nyse: abbv) were down by 4% on sky-high volume as of 11 a.m. et thursday. thats equivalent to a $7 billion drop in market capitalization.

Thu Jun 1, 2023

Momentum

abbvie says upadacitinib 30 mg meets primary goals in sle patients in mid-stage study. (rttnews) - abbvie inc. (abbv) a clinical-stage pharmaceutical company wednesday announced the results of its phase 2 sleek study evaluating upadacitinib (ri

Wed May 31, 2023

Activity

2 dividend kings on sale that are yielding more than 4%. dividend kings have excellent track records for dividend growth and are often seen as some of the safest income investments to own. two dividend growth stocks that may look tempting and th

Thu May 25, 2023

Activity

oversold conditions for abbvie. legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful. one way we can try to measure the level of fear in a given stock is through a technical an

Wed May 24, 2023

Momentum

abbvie (abbv) gets fda nod for lymphoma drug epcoritamab. abbvie abbv and partner genmab gmab announced that the fda has granted accelerated approval to their t-cell engaging bispecific antibod

Mon May 22, 2023

Activity

abbvie genmab granted fda nod for lymphoma therapy.

Fri May 19, 2023

Activity

us fda approves genmab-abbvies blood cancer therapy. the United States food and drug administration has approved abbvie inc and danish drugmaker genmabs experimental blood cancer therapy for adult patients who have received at least two prior li

Fri May 19, 2023

Activity

abbvies (abbv) rinvoq gets fda nod to treat crohns disease. abbvieabbv announced the fda approval of its immunology drug rinvoq (upadacitinib) a once-daily pill for the treatment of adults with moderately to severely active crohns dise

Fri May 19, 2023

Activity

fda approves abbvies rinvoq as once-daily pill for crohns disease in adults. (rttnews) - the United States food and drug administration approved abbvies (abbv) rinvoq or upadacitinib for the treatment of adults with moderately to severely active

Fri May 19, 2023

Activity

allergan aesthetics says fda approves skinvive by juvederm. (rttnews) - allergan aesthetics an abbvie company (abbv) announced monday the United States fda approval of skinvive by juvederm to improve skin smoothness of the cheeks in adults over

Mon May 15, 2023

Activity
Potential

this is what whales are betting on abbvie. a whale with a lot of money to spend has taken a noticeably ish stance on looking at options history for abbvie (nyse:) we detected 14 strange trades. if we consider the specifics of each trade it is accurate

Thu May 11, 2023

Activity
Potential

unusual put option trade in abbvie (abbv) worth $4742.50k. on may 10 2023 at 15:19:36 et an unusually large $4742.50k block of put contracts in abbvie (abbv) was bought with a strike price of $160.00 / share expiring in 9 da

Thu May 11, 2023

Momentum

unusual put option trade in abbvie (abbv) worth $11130.00k. on may 10 2023 at 15:19:36 et an unusually large $11130.00k block of put contracts in abbvie (abbv) was bought with a strike price of $165.00 / share expiring in 37

Thu May 11, 2023

Momentum

abbvie: a rise in the incidence of ibd could boost profits.

Wed May 10, 2023

Earnings

abbvie: a rise in the incidence of ibs could boost profits.

Wed May 10, 2023

Earnings

abbvies rinvoq gets approval in canada for expanded use in axial spondyloarthritis.

Tue May 9, 2023

Activity

looking at abbvies recent unusual options activity. a whale with a lot of money to spend has taken a noticeably bearish stance on looking at options history for abbvie (nyse:) we detected 11 strange trades. if we consider the specifics of each trade it

Mon May 8, 2023

Activity
Activity
Momentum
Potential

heres how much $1000 invested in abbvie 10 years ago would be worth today. abbvie (nyse:) has outperformed the market over the past 10 years by 3.1% on an annualized basis producing an average annual return of 12.85%. currently abbvie has a market capital

Fri May 5, 2023

Activity

2 things about abbvie that investors are ignoring. investors were ready for declines in abbvies (nyse: abbv) blockbuster immunology drug humira. the product now is facing competition in the United States so seeing a 26% drop in humiras United St

Wed May 3, 2023

Momentum

abbvie sells off i am buying.

Wed May 3, 2023

Momentum

unusual put option trade in abbvie (abbv) worth $1585.00k. on may 1 2023 at 11:32:44 et an unusually large $1585.00k block of put contracts in abbvie (abbv) was sold with a strike price of $150.00 / share expiring in 627 day

Tue May 2, 2023

Momentum

notable monday option activity: abbv orcl mtch. among the underlying components of the s&.p 500 index we saw noteworthy options trading volume today in abbvie inc (symbol: abbv) where a total of 27571 contracts have traded so far represen

Mon May 1, 2023

Momentum

guggenheim maintains abbvie (abbv) buy recommendation. fintel reports that on april 28 2023 guggenheim maintained coverage of abbvie (nyse:abbv) with a buy recommendation.

Fri Apr 28, 2023

Rating

morgan stanley maintains abbvie (abbv) overweight recommendation. fintel reports that on april 28 2023 morgan stanley maintained coverage of abbvie (nyse:abbv) with a overweight recommendation.

Fri Apr 28, 2023

Rating

wells fargo maintains abbvie (abbv) overweight recommendation. fintel reports that on april 28 2023 wells fargo maintained coverage of abbvie (nyse:abbv) with a overweight recommendation.

Fri Apr 28, 2023

Rating

why abbvie stock is crashing today. what happened shares of the pharmaceutical giant abbvie (nyse: abbv) fell by as much as 9% in early morning trading thursday. the drugmakers shares have recovered since hitting this intra-day low but they wer

Thu Apr 27, 2023

Momentum

thursday sector laggards: healthcare energy. the worst performing sector as of midday thursday is the healthcare sector not showing much of a gain. within that group align technology inc (symbol: algn) and abbvie inc (symbol: abbv) are two

Thu Apr 27, 2023

Momentum

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ABBV alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ABBV AbbVie

Last Price
139.04
Change
+1.02%
 

Summary

  Login to display AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.

 
 
153.95
154.22
144.84
152.49
 
 
1m
3m
6m
1y
 
Sentiment

Strengths

Rewards

 Investors confidence is positive

Rewards

 Trading below its fair value

Rewards

 Pays a reliable dividend

Risk Analysis

Risk Analysis

 Earnings are forecast to decrease

Risk Analysis

 Downgraded on weak valued

Risk Analysis

 Enter oversold territory

Risk Analysis

 Insider selling during the past 3 months

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
67%
0%
60%
On Track
On Track
On Track
 
47%
43%
Positive
Negative
37 out of 79
events present
34 out of 79
events present
 

Street Opinion

Street view is bullish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

2.91
 

StocksRunner

 Earnings decline YoY

StocksRunner

 Sales decline

 
 

Rating

×
 

Rating

3.67
 

StocksRunner

 Downgraded on weak valued

 

Momentum

×
 

Momentum

2.22
 

StocksRunner

 Price value has negative momentum

StocksRunner

 Enter oversold territory

 

Activity

×
 

Activity

3.62
 

StocksRunner

 Investors confidence is positive

StocksRunner

 Pays a reliable dividend

StocksRunner

 Insider selling during the past 3 months

 

Future

×
 

Future

3.40
 

StocksRunner

 Earnings are forecast to decrease

StocksRunner

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

AbbVie (ABBV) has Low Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Investors Selling
This Week
136.87
+2.57%
 
Options Activity
3 Weeks Ago
146.56
+0.11%
 
Strong Earnings
3 Weeks Ago
146.52
-0.21%
 
Investors Selling
2 Month Ago
147.26
-0.52%
 
Options Activity
2 Month Ago
152.03
-1.09%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ABBV Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines